Physician profile
Ellen D Teplitz
NPI 1174683742
$10,455.71
in general payments reported to CMS, 2019-2025
32 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $445 · 2021: $945 · 2022: $2,310 · 2023: $1,919 · 2024: $1,549 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,871 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,871.19 |
| Education | $357.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.90 | 2021-2025 | Rinvoq |
| Amgen INC. | $1,319.26 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $939.56 | 2019-2025 | |
| Incyte Corporation | $750.30 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $740.59 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $693.64 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $673.01 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $636.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $609.06 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $360.85 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $340.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $304.76 | 2019-2025 | |
| Ucb, INC. | $260.70 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $225.15 | 2019-2025 | Aklief, Nemluvio |
| Mayne Pharma Commercial LLC | $197.08 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $188.59 | 2019 | |
| Epi Health, LLC | $131.24 | 2019-2020 | |
| Biofrontera INC. | $85.98 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $71.96 | 2020-2021 | |
| Almirall LLC | $69.12 | 2019-2021 | |
| Genentech USA, INC. | $65.84 | 2019 | |
| Dermavant Sciences, INC. | $59.17 | 2023-2024 | Vtama |
| Organon LLC | $54.46 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.17 | 2019 | |
| Paratek Pharmaceuticals, INC. | $48.91 | 2023-2024 | Nuzyra |
| Merz North America, INC. | $34.33 | 2019 | |
| Prugen, INC. Pharmaceuticals | $30.79 | 2019 | |
| Promius Pharma LLC | $29.31 | 2019 | |
| Allergan, INC. | $24.30 | 2019 | |
| Dermira, INC. | $19.32 | 2020 | |
| Sandoz INC. | $17.17 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.13 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Teplitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.